Invention Grant
- Patent Title: High-sensitivity sequencing to detect BTK inhibitor resistance
-
Application No.: US15239542Application Date: 2016-08-17
-
Publication No.: US10253370B2Publication Date: 2019-04-09
- Inventor: Maher Albitar
- Applicant: Neogenomics Laboratories, Inc.
- Applicant Address: US FL Fort Myers
- Assignee: NEOGENOMICS LABORATORIES, INC.
- Current Assignee: NEOGENOMICS LABORATORIES, INC.
- Current Assignee Address: US FL Fort Myers
- Agency: Musick Davison, LLP
- Agent Eleanor Musick
- Main IPC: C12Q1/68
- IPC: C12Q1/68 ; C12Q1/6886
Abstract:
A method for predicting resistance to BTK inhibitors in patients with chronic lymphocytic leukemia (CLL) enhances the sensitivity of Sanger sequencing and NGS by using wild-type blocking of genes that are relevant for detecting resistance to ibrutinib. Further enhancement of sensitivity can be achieved by using cell-free DNA.
Public/Granted literature
- US20170051357A1 HIGH-SENSITIVITY SEQUENCING TO DETECT BTK INHIBITOR RESISTANCE Public/Granted day:2017-02-23
Information query
